3 Uncomfortable Truths About Cell and Gene Therapy in Regulatory Affairs

The story we would like to tell about cell and gene therapy (CGT) is straightforward: science is advancing, regulators are modernizing, approvals are rising and patients will benefit. The latest regulatory report we have done in collaboration with the International Society for Cell & Gene Therapy shows that story is only half true. The other half is messier, more consequential, and more urgent.

Here are three truths that are difficult to ignore. They are grounded in what the clinical trial pipeline, registration approvals, withdrawals, and regulatory activity are actually revealing.

Truth #1: CGT does not have an innovation problem but rather a delivery problem.

The pipeline is active: 322 global clinical trials across regions, dominated by Phase I/II activity. Genetically modified cell therapies account for 53% of trials, with gene therapies building momentum.

But here is the uncomfortable part: a large pipeline does not automatically translate into a large patient impact. When most activity sits in early phases, it signals not just innovation but also high attrition, long timelines, and repeated reinvention.

The market is sending signals that the breakthrough-to-blockbuster path is not reliable. The report documents product withdrawals/cancellations for reasons including limited demand and pricing issues rather than scientific failure.

This means that CGT is colliding with a reality where manufacturing complexity, comparability, site readiness, and post-approval evidence generation determine success as much as clinical efficacy.

What to do about it:

Treat CMC and comparability as a strategic function, not a technical afterthought. If your comparability strategy wouldn’t survive a scale-up, you don’t have a program but rather a pilot.
Design for operations early: chain-of-identity, release logistics, site qualification, and long-term follow-up should not start after pivotal.
Stop optimizing only for approval. Optimize for repeatable delivery.

Truth #2: Regulatory accelerated pathways are now table stakes but it will not save weak evidence strategies.

Regulatory agencies are actively reshaping the roadmap to market:

The report highlights global emphasis on adaptive trial design guidance (ICH E20) and FDA draft guidance on innovative designs for small populations, among key updates.
It also notes that 71 CGT guidances were issued in 2025, reflecting how rapidly regulators are refining expectations.

This looks like progress, but the uncomfortable truth is that accelerated pathways can amplify weak development strategies just as quickly as they accelerate good ones.

When programs are built around getting through the gate, they often underinvest in:

Durability endpoints and long-term follow-up planning
External comparators and real‑world evidence architecture
Pediatric/label expansion logic early enough to matter
Post-approval commitments that are feasible rather than theoretical

The report’s withdrawals and suspensions, including safety-related actions, are a reminder: post-approval is where CGT reputations are made.

This means that regulators are increasingly willing to be flexible on how you generate evidence, but not on whether you can sustain it across the product lifecycle.

What to do about it:

Build a lifecycle evidence blueprint at the same time you build the pivotal study.
Use innovative designs, but pair them with credible confirmatory and post-market plans.
Plan for label credibility, not just label speed.

Truth #3: Global development is no longer U.S./E.U. first. The center of gravity is drifting fast.

Companies still behave as if the world is sequential: start in the U.S., validate in the E.U., then expand to rest of the world. But the regulatory activity points to a more multipolar reality:

The clinical pipeline is meaningfully distributed across North America, Europe, and Asia, with substantial activity across phases.
Guidance issuance is also shifting: Japan leads in the number of guidances, with Taiwan second, and the report highlights multiple Asia‑Pacific legislative and framework moves.
Meanwhile, the submission pipeline shows regional differences in what’s being filed, e.g., gene therapy dominance in North America, and no submissions reported in LATAM/MEA/ANZ in the period captured, hinting it is still not global.

This creates a strategic discomfort: regulatory influence and development speed are not confined to the traditional hubs, and competitive advantage can emerge from markets many companies still treat as a later strategy.

This means global strategy is shifting from sequencing to orchestration. Those who can’t operate in a world where requirements evolve in parallel will be outpaced by those who can.

What to do about it:

Move from global roll‑out thinking to global design thinking: design the program to satisfy multiple regulators early.
Establish an Asia‑informed regulatory intelligence loop as a core capability, not an occasional check.
Don’t treat LATAM/MEA/ANZ as peripheral; instead, treat them as access strategy puzzles you solve upfront.

In summary, the next chapter for CGT will demand:

Regulatory harmonization across markets
Innovative pricing and reimbursement models
Scalable manufacturing and supply chains
Earlier integration of regulatory strategy into R&D

The CGT sector has enough innovation. What it lacks is the infrastructure of evidence, manufacturing, access, and sustained regulatory alignment required to convert breakthrough biology into routine medical care.

You can read the full regulatory report here: Cell and Gene Therapy Regulatory Report

Consulting Resource Center Regulatory